HK inno.N Strengthens Competitiveness in IV Fluid Market by Securing Flu Treatment Injection
Domestic pharmaceutical company HK inno.N is enhancing its market competitiveness by recently securing a new flu treatment injection in an IV bag format. The newly introduced product is a flu treatment containing peramivir hydrate, which is expected to provide a more convenient administration environment for patients.
HK inno.N has established a strong position in the domestic IV fluid market. Through the acquisition of this flu treatment, the company plans to further diversify its existing IV fluid portfolio and focus on broadening the range of options for patients and medical staff.
IV bag formulations have the advantage of being easier to store and use compared to traditional bottle formats. Given the high number of patients visiting hospitals during the winter flu season or transitional periods, the introduction of this product is expected to contribute to increased efficiency in clinical settings.
Recently, there has been growing interest in disease prevention in the medical community, such as the link between diabetes and pancreatic cancer. In a climate where the importance of health management is increasing, such efforts by pharmaceutical companies to improve products are evaluated as having a positive impact on the promotion of public health.
Moving forward, HK inno.N intends to continue supplying a variety of treatments stably as a leader in the IV fluid market. The industry is closely watching how much this flu treatment launch will improve treatment convenience for patients in Korea.